Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing

Stock Information for Immunic Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Immunic Inc.

Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December
Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Immunic to Participate in Industry and Investor Conferences in November
Immunic to Participate in Scientific and Investor Conferences in October
Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis
Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis
Immunic to Participate in Investor and Scientific Conferences in September
Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.